Organization & Developments: Fluidigm

Parents

Developer of products based on integrated fluidic circuits that enable increased efficiency in a variety of life science applica
Each BioMark HD microfluidics platform has the capacity to process thousands of SARS-CoV-2 PCR tests per day with a primary focus on saliva samples.
Fluidigm has developed microfluidic chips that can precisely control nanoliters of liquid.
Fluidigm sells its chips to them for use in processes such as gene sequencing, single-cell analysis, and agricultural genotyping
Scientists can use these chips to analyze gene expression in single cells, to identify mutations in cells, and to grow stem cell
With many existing Fluidigm instruments in clinical and research labs throughout the United States, scale up and deployment of their advanced integrated fluidic chips can provide tens to hundreds of thousands of new tests per day in fall 2020.